Akers Biosciences Nets USD49,000 From Warrants Exercise (ALLISS)

Fri, 16th Mar 2018 18:11

LONDON (Alliance News) - Akers Biosciences Inc, a developer of health screening and testing products, said Friday that it has netted USD48,750 from warrants exercise.

The company received exercise notices from warrant holders to exercise warrants over an aggregate 260,000 shares of common stock, with an exercise price of 18.75 cents per share. The warrants were granted pursuant to the public offering announced on December 19, 2017.

Shares in the company closed at 49.45 pence, down 1.1%.

Related Shares

More News

8 Oct 2018 13:10

Akers Biosciences appoints chief executive after settling legal battle

(Sharecast News) - Akers Biosciences appointed Howard Yeaton as chief executive on Monday as the company reached a settlement in its legal dispute wit...

15 Aug 2018 08:04

Akers Biosciences profits hit over antigen difficulties

(Sharecast News) - Akers Biosciences' losses burgeoned as second-quarter revenues were cut in half after softer sales of its flagship Heparin rapid as...

3 Apr 2018 13:45

Akers Biosciences 2017 Revenue Rises But Loss Widens On Higher Costs

LONDON (Alliance News) - Akers Biosciences Inc on Tuesday said revenue grew in 2017, but its loss widened due to increased costs across the business.T...

16 Feb 2017 08:44

Akers Biosciences gains US patent for disposable cartridge

(ShareCast News) - Akers Biosciences, a developer of rapid health information technologies, has been granted a US patent for its wellness disposable m...